(Photo: ASH)
Winship Cancer Institute of Emory University blood disease experts — including faculty, staff and trainees from Emory, Georgia Tech and Children’s Healthcare of Atlanta — will present emerging pre-clinical, epidemiological and clinical data in blood cancers and blood disorders at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, Dec. 6-9, 2025.
With more than 18,000 members representing 100 countries, ASH is the world’s largest professional society serving clinicians and scientists who are working to make progress against blood diseases. Its annual meeting is a global destination for hematology professionals and drew more than 30,000 attendees last year.
From chairing symposia to presenting promising new treatment approaches for blood malignancies and benign blood diseases, Winship investigators will participate in 97 sessions at this year’s meeting. Pre-conference workshops and symposia include the 14th Annual BMT & Cell Therapy Winter Workshop on Dec. 5, which is co-chaired by Winship hematologist Edmund K. Waller, MD, PhD, FACP, and covers unpublished clinical and pre-clinical data relevant to hematopoietic stem cell transplantation and cell therapy.
“As the hematology programs at Winship continue to expand in their national and global prominence in research, patient care and education, it is particularly gratifying to see the record number of abstracts being presented at this year’s ASH meeting,” says Winship physician-researcher David A. Frank, MD, PhD, FACP, director of the Division of Hematology in Emory University School of Medicine’s Department of Hematology and Medical Oncology. “Many of the presenting authors are students or trainees, which reflects the phenomenal teaching and mentorship provided by our faculty. Furthermore, a growing number of the senior authors on the research being presented are in the early stage of their faculty careers. This suggests that the impact of our hematology programs will continue to grow briskly in the years ahead.”
This year, several early-career Winship researchers were selected for special ASH awards that recognize the accomplishments of hematologists-in-training. Hematology and medical oncology fellow Abraham Attah, MD, received a 2025 ASH Hematology Inclusion Pathway (HIP) Fellow Award, which provides salary support and funding for blood science-focused research projects. Attah is also one of the following 20 Emory trainees to receive an ASH Abstract Achievement Award given to presenting authors of high-scoring annual meeting abstracts:
- James Ackley
- Shree Allada
- Akshaya Arjunan, MD
- Abraham Attah, MD
- Anna Baj
- Karanpreet Bhatia
- Robert Chavez
- Kennedy Goldsborough, PhD
- Dunia Hatabah, MD
- Rawan Korman, MD
- Stella Lee
- Yun Li, PhD
- Dominique Mosley, MD
- Joshua Muniz, MD
- Tinatin Muradashvili, MD
- Abhinav Pasupuleti
- Om Raval
- Silvia Juarez Rojas
- Anna Schwartz
- Mohamad Ali Tfaily, MD, MS
Schedule of Winship and Emory Presentations
7:00 a.m. - 10:00 a.m.
Location: Hyatt - Plaza Int'l HIJK | Friday Satellite Symposia | Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and non-BCMA Immunotherapies
3:00 p.m. - 6:00 p.m.
Location: OCCC - W315 | Scientific Workshops | Scientific Workshop on Disease Severity Scoring and Clinical Trial Endpoints Beyond Vaso-Occlusive Pain in Sickle Cell Disease
- Dunia Hatabah, MD
3:05 p.m. - 3:45 p.m.
Location: OCCC - W315 | Scientific Workshops | Disease Severity Scoring in Sickle Cell Disease
4:35 p.m. - 5:15 p.m.
Location: OCCC - W315 | Scientific Workshops | Acute Vaso-occlusive Pain Clinical Trial Endpoints Beyond Time-to-Crisis-Resolution in Sickle Cell Disease (SCD)
- Claudia R. Morris, MD | Challenges with Time-to-Crisis-Resolution as an Endpoint in Acute SCD Pain Clinical Trials
5:13 p.m. - 5:53 p.m.
Location: OCCC - W414CD | Scientific Workshops | Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
8:00 a.m. - 9:00 a.m.
Location: Hyatt - Bayhill 20 | Meet the Scientist
10:45 a.m. - 11:00 a.m.
Location: OCCC - W311ABCD | Oral Abstract Session | 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression
- William Briones | Deep neutrophil phenotyping uncovers complement-mediated neutrophil dysregulation in sickle cell disease
11:15 a.m. - 12:15 p.m.
Location: Hyatt - Windermere Ballroom | Trainee Activities and Services Career Development Lunch
4:00 p.m. - 4:20 p.m.
Location: OCCC - W414CD Special-Interest Sessions | ASH Clinical Practice Guidelines on Myelofibrosis
- Anthony Hunter, MD | Myelofibrosis Recommendation Highlights: Next-Generation Sequencing (NGS), Aspirin Therapy, and Iron Chelators
4:45 p.m. - 5:00 p.m.
Location: OCCC - Tangerine Ballroom F1 | Oral Abstract Session | 621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers
- Jean Koff, MD, MSc | Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status
5:00 p.m. - 5:15 p.m.
Location: OCCC - Valencia Room W415BC | Oral Abstract Session | 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel AML Biomarkers: Mechanisms, Mutations, and Targets
- Janghee Woo, MD, PhD | Mechanistic dissection of venetoclax sensitivity in AML through single-molecule BCL2 protein complex profiling and mutation-specific apoptotic rewiring
5:00 p.m. - 5:15 p.m.
Location: OCCC - West Hall E2 | Oral Abstract Session | 907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care
- Jonathan Kaufman, MD | Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
6:30 p.m. - 8:00 p.m.
Location: Hyatt - Florida Ballroom A | Special-Interest Sessions | Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology I
- Dejah Blake, MS | The impact of heme modulation on CAR T cell therapy
6:30 p.m. - 8:00 p.m.
Location: Hyatt - Plaza Int'l F | Special-Interest Sessions | Hematology Inclusion Pathway (HIP) Oral Presentations – Health Services Outcomes
- Dominique Mosley, MD | Characterizing a racially diverse cohort of patients with AL amyloidosis treated with daraVCD
5:30 p.m. - 7:30 p.m.
Location: OCCC - West Halls B3-B4 | Poster Abstract Session
- Akshaya Arjunan, MD | Complement dysregulation during vaso-occlusive episodes can predict development of acute chest syndrome in pediatric patients with sickle cell disease
- Abraham Attah, MD | Prophylactic transfusion in pregnant in women with sickle cell disease (ProTIP)
- Waitman Aumann, MD | A novel role for SIX1 and EYA2 and a novel EYA2 inhibitor in myeloid leukemogenesis
- Tarun Aurora, MD, MSCI | Empowering families through conversational design: A chatbot for sickle cell care
- Tarun Aurora, MD, MSCI | Tailoring pediatric to adult care transition from high to low-resource settings: A usercentered design approach
- Tisha Boodooram | Cerebral hemodynamic changes during vaso-occlusive episodes in pediatric sickle cell disease
- Dailia Francis, MD, PhD | Siglec-15 dependent alteration of the leukemia immune microenvironment
- Sara Graciaa, MSN, CPNP | Complement inhibition in pediatrics: Comprehensive infection analysis from a large pediatric single center
- Muhammad Saad Hamid | Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study
- Charles Jonassaint, PhD | Feasibility of wearable technology for remote monitoring in high-risk adults with sickle cell disease: Baseline data from the SCD-carre trial
- Nisha Joseph, MD | Advancing adoption of evidence-based quadruplet treatment regimens for newly diagnosed multiple myeloma in community practice: Insights from a quality improvement initiative
- Nisha Joseph, MD | Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with relapsed/refractory multiple myeloma
- Nisha Joseph, MD | Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor Tcell in Relapsed/Refractory multiple myeloma
- Jedrzej Konarkowski | Sight: Sickle cell identification from general hematological testing, a machine learning approach for rapid screening in emergency medicine
- Kiran Lakhani | Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and European ancestries
- Stella Lee | Simultaneous PD-1 and VIP receptor blockade optimizes tumor immunotherapy in P815 acute myeloid leukemia model
- Siddhartha Mantrala | Myscape: Myeloma single cell atlas for precision exploration reveals stage-specific T cell dysregulation associated with progression and therapy
- Shannon Matulis | Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming
- Sonia Mecorapaj | A VPAC1/2-targeted antagonist, preferentially binds to activated T cells and enhances T cell activation
- Tamara Miller, MD, MSCE | Association between COMT activity and development of infections during therapy for pediatric acute lymphoblastic leukemia
- Ahmad Nassar, MBBS | A fellow-led communication skills training curriculum for hematology/oncology trainees
- Ajay Nooka, MD, MPH | Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients
- Ashwin Patel, MBBS, PhD | Red cell rheology predicts acute chest syndrome and vaso-occlusive events in sickle cell disease
- William Pilcher | Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes
- Om Raval | Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance
- Robert Sidonio Jr, MD, MSc | Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von Willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective
- Jason Stevenson, MD, MSCR | Association of race and ethnicity and incidence and severity of hyperglycemia and clinically-treated hypertension during induction therapy for pediatric acute lymphoblastic leukemia
- Janghee Woo, MD, PhD | Clonal hematopoiesis drives T cell dysregulation and immune remodeling revealed by GWAS-based mendelian randomization and single-cell transcriptomics
- Justin Yoo, MD, MS | Optimization of stem cell fitness and mobilization using moderate transfusion and an oral anti-sickling agent in the sickle mouse model
10:00 a.m. - 10:15 a.m.
Location: OCCC - W308 | Oral Abstract Session | 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Orphans of an orphan disease: HbSC and HbSBeta+ Sickle Cell Disease
- Abraham Attah, MD | Hemoglobin S beta thalessemia plus: Clinical analysis from the Georgia Comprehensive Sickle Cell Center at Grady Memorial Hospital, Atlanta, Georgia
12:15 p.m. - 12:30 p.m.
Location: OCCC - West Hall E1 | Oral Abstract Session | 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Emerging Myeloma Disease Mechanisms and Therapeutic Strategies
12:30 p.m. - 12:45 p.m.
Location: OCCC - W311ABCD | Oral Abstract Session | 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: On the Horizon: Biomarkers Guiding Outcomes in Hemoglobinopathies
- Tara Urner, PhD | Cerebral hemodynamic response to chronic transfusion is associated with cerebral vasculopathy in sickle cell anemia
5:15 p.m. - 5:30 p.m.
Location: OCCC - W311ABCD | Oral Abstract Session | 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Therapies in Sickle Cell Disease: Finding Progress in Existing Drugs
- Claudia R. Morris, MD | Sickle cell disease treatment with arginine therapy (STArT) – results of a phase 3 randomized controlled trial
5:15 p.m. - 5:30 p.m.
Location: OCCC - Valencia Room W415D | Oral Abstract Session | 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance mechanisms and targeting approaches
- Karanpreet Bhatia | Dissection of non-genetic resistance mechanisms by lineage tracing and single cell multiomics reveals drug-specific persister programs in acute myeloid leukemia
6:00 p.m. - 8:00 p.m.
Location: OCCC - West Halls B3-B4 | Poster Abstract Session
- James Ackley | Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma
- Shree Allada | CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)
- Martha Arellano, MD | Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study
- Waitman Aumann, MD, MS | Inotuzumab ozogamacin in refractory or 1st or greater relapse of pediatric B-ALL as bridge to cure: A single center experience
- Tarun Aurora, MD, MSCI | Development of the sickle cell outcome grading system (SCOGS), a novel classification system for sickle cell disease severity
- Tarun Aurora, MD, MSCI | Prevalence and factors associated with acute transfusion reactions among patients receiving blood transfusions in regional referral hospitals in Dar Es Salaam, Tanzania
- Robert Chavez | NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma
- Zihan Chen | VIP, a novel phagocytosis checkpoint in TP53-mutated acute myeloid leukemia
- Dunia Hatabah, MD | Revisiting acute chest syndrome (ACS) associated with sickle cell disease (SCD) vasoocclusive pain episodes (VOE): Insight from a prospective, multicenter Phase-3 randomized controlled trial
- Laneisha Maldonado Jaime, MD | Determining barriers to access first-line treatment in high volume facilities in adolescents and young adults (AYA) with acute leukemias
- Nisha Joseph, MD | Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
- Grace Kalmus | Incidence and risk factors for new overweight or obesity following hematopoietic cell transplantation for sickle cell disease
- Rawan Korman, MD | Secretory phospholipase A2 (sPLA2) during vaso-occlusive pain episodes (VOE) and acute chest syndrome (ACS) in sickle cell disease (SCD): Results from a prospective multi-center randomized controlled trial (RCT)
- Isabella Lin | A chronotherapeutic approach to VIP receptor antagonist (ANT308) in anti-tumor activity
- Sagar Lonial, MD, FACP, FASCO | Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments
- Sagar Lonial, MD, FACP, FASCO | Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7
- Tamara Miller, MD, MSCE | Optimizing high-dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia
- Elizabeth Minten, MD, PhD | Correlation between outpatient opioid dosage and hospital visits in sickle cell disease patients
- Dominique Mosley, MD | Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD
- Silvia Juarez Rojas | Association of factor VIII inhibitors with genetic variants implicated in immune dysregulation
- Yumiko Sakurai, MS | A protein S-targeting monoclonal antibody, VGA039, improves both primary and secondary hemostatic activity of von Willebrand disease patient blood in an ex vivo vascularized hemostasis-on-a-chip
- Vivien Sheehan, MD, PhD | In vitro and in vivo FOXO3 dependent induction of fetal hemoglobin
- Mohamad Ali Tfaily, MD, MS | Outcomes of arthroplasty in persons with hemophilia: A survey of Medicare data
- Nithin Thomas, MBBS | Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism
- Kirsten Williams, MD | Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study
- Lawrence Wilson | EMU-116: An oral CXCR4 antagonist as mobilizer of stem and immune cells in normal, neutropenic and sickle cell mice
10:30 a.m. - 11:45 a.m.
Location: OCCC - West Hall D1 | Education Program | Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit
4:30 p.m. - 4:45 p.m.
Location: OCCC - W331 | Oral Abstract Session | 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects
- Elizabeth Stenger, MD, MSc | Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis
4:45 p.m. - 5:00 p.m.
Location: OCCC - W331 | Oral Abstract Session | 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects
5:30 p.m. - 5:45 p.m.
Location: OCCC - West Hall E1 | Oral Abstract Session | 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Determinants of Immunotherapy Response in Multiple Myeloma
- Angelica Amanso | Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells
5:30 p.m. - 5:45 p.m.
Location: OCCC - Sunburst Room (W340) | Oral Abstract Session | 801. Gene Therapies: Technological Developments in Gene Therapy
- Janghee Woo, MD, PhD | Scalable, Antibody-Free Lipid Nanoparticle Achieves Human HSPC-Selective mRNA Delivery In Vivo Without Conditioning
6:00 p.m. - 8:00 p.m.
Location: OCCC - West Halls B3-B4
- Mary Aliche | Development of whole blood viscosity measurements under hypoxia for use in sickle cell disease
- Abraham Attah, MD | Chronic kidney disease risk stratification in compound sickle cell disease variants: A single center review
- Satheesh Chonat, MD | Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebocontrolled ACTIVATE-Kids trial
- Kennedy Goldsborough, PhD | IHP-102 reduces pain and modulates complement activation in a sickle cell mouse model
- Vikas Gupta, MD, PhD | Functional genomic screens identify positive and negative regulators of venetoclax resistance
- Almeera Lateef, MD | Role of race in severity and survival of those with cutaneous T-cell lymphoma
- Maria Leon-Camarena, MD | High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost
- Yun Li, PhD | CD43 functions as a CD47 independent “don’t eat me” signal and novel immune checkpoint in AML
- Joshua Muniz, MD | Association between adolescent and young adult (AYA) age, acuity of illness at diagnosis, and clinical trial enrollment among patients with hematologic malignancies at a pediatric center
- Tinatin Muradashvili, MD | Mortality patterns and geographic variation in acquired hemophilia A among Medicare beneficiaries in the United States
- Ajay Nooka, MD, MPH | Final results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study
- Nneka Nwachukwu, MD | Pregnancy related complications and placenta pathology in pregnant women with sickle cell disease
- Abhinav Pasupuleti | Use of red cell deformability measurements to assess the impact of pyruvate kinase activators on combined drug and transfusion therapies
- Kayla Robinson | VIP pathway inhibition alters microbial metabolism to balance graft-versus-leukemia and GVHD
- Anna Schwartz | Rates of inhibitor development and immune tolerance in children with severe Hemophilia A on emicizumab prophylaxis
- Soumitri Sil, PhD, ABPP | Randomized controlled trial-in-progress of an interdisciplinary treatment program for youth with chronic SCD pain: Integrative strong body and mind training for sickle cell disease (I-STRONG)
- Robert Sidonio Jr, MD, MSc | Real-world study of population pharmacokinetic-guided pdVWF/FVIII (1:1) prophylaxis in people with severe von Willebrand disease: The PopPK-WILPROPHY study